IL2 and breast cancer: To test whether we would see better outcomes in tumors that express higher levels of EIIIB + FN, we also tested the anti-EIIIB IL-2 fusions i.v. as a monotherapy in the 4T1 orthotopic breast cancer model, which has been shown to express more EIIIB than the B16F10 model (9) (Fig. 3C).